DTX101: Phase I/II started

Dimension began an open-label, U.S. Phase I/II trial to evaluate 4 dose levels of DTX101 in about 12 adult male patients. In 2013, RegenxBio granted Dimension an exclusive, worldwide license to NAV ve...